Financial Performance - Total revenues for the three months ended September 30, 2024, were $1,196, an increase of $1,186 compared to $10 for the same period in 2023, primarily driven by contributions from Myrtle and RCHI acquisitions [268]. - Net loss attributable to FOXO for the three months ended September 30, 2024, was $(1,946), a decrease of $1,714 compared to $(3,660) for the same period in 2023 [268]. - The company recognized a net loss of $(2,034) to common stockholders for the three months ended September 30, 2024, compared to $(4,572) for the same period in 2023, a reduction of $2,538 [268]. - Net loss attributable to FOXO improved to $1,946 for the three months ended September 30, 2024, a 47% reduction from a net loss of $3,660 in the same period of 2023 [276]. - Net revenues for the nine months ended September 30, 2024, were $1,231, a significant increase from $35 in the same period of 2023, representing a change of $1,196 [284]. - Net loss attributable to FOXO for the nine months ended September 30, 2024, was $5,613, an improvement of 75% compared to a net loss of $22,592 in the same period of 2023 [292]. - Net losses available to common stockholders were $6,667,000 for the nine months ended September 30, 2024, compared to $25,970,000 in 2023 [303]. - Adjusted EBITDA for the nine months ended September 30, 2024 was $(597,000), an improvement from $(4,785,000) in 2023 [302]. Costs and Expenses - Direct costs of revenues increased to $541 for the three months ended September 30, 2024, from $70 in the same period of 2023, attributed to the direct costs associated with Myrtle and RCHI [270]. - Research and development expenses decreased to $43 for the three months ended September 30, 2024, from $283 in the same period of 2023, a reduction of 85% [271]. - Selling, general and administrative expenses were $1,733 for the three months ended September 30, 2024, down 63% from $4,717 in the same period of 2023, a decrease of $2,984 [274]. - Direct costs of revenues increased to $572 for the nine months ended September 30, 2024, compared to $70 in the same period of 2023, a rise of 717% [285]. - Research and development expenses for the nine months ended September 30, 2024, were $312, down 66% from $925 in the same period of 2023 [286]. - Selling, general and administrative expenses decreased to $4,195 for the nine months ended September 30, 2024, from $15,052 in the same period of 2023, a reduction of $10,857 or 72% [289]. Acquisitions and Business Strategy - The healthcare segment began operations with the acquisition of Myrtle on June 14, 2024, and expanded with the acquisition of RCHI on September 10, 2024, focusing on substance abuse treatments and hospital services [261]. - FOXO entered into a KR8 Agreement on October 29, 2023, to develop a Direct-to-Consumer APP utilizing AI technology for epigenetic biomarker applications [250]. - The company completed the acquisitions of Myrtle and RCHI on June 14, 2024, and September 10, 2024, respectively, with RCHI expected to provide positive operating cash flows [341]. - The company expects the Myrtle and RCHI businesses to be cash flow neutral through the remainder of 2024 [319]. Financial Position and Cash Flow - Cash and cash equivalents were $34,000 as of September 30, 2024, down from $38,000 at the end of 2023 [303]. - The company has a working capital deficit of $31,439,000 and a total stockholders' deficit of $17,554,000 as of September 30, 2024 [303]. - The company is negotiating additional funding with multiple sources to support its business strategy [304]. - For the nine months ended September 30, 2024, the company used net cash of $995, a significant improvement from $6,165 used in the same period in 2023, primarily due to a $16,979 reduction in net loss [325]. - The company has contractual obligations totaling $50,291, with $13,231 due within one year [330]. - The company reported a total stockholders' deficit of $31,439 as of September 30, 2024, compared to $17,554 in the previous year [338]. - The company has $34 of available cash and cash equivalents as of September 30, 2024 [338]. Risks and Uncertainties - Recent acquisitions of Myrtle and RCHI may increase operational risks for the company [349]. - Economic uncertainties include downturns in financial markets, inflation, and rising oil prices [349]. - The company faces potential impacts from supply chain disruptions and declines in consumer confidence [349]. - Geopolitical instability, such as military conflicts in Ukraine and Israel, could adversely affect operations [349]. - The resurgence of the COVID-19 pandemic and new variants remain a concern for business stability [349]. - The company is subject to noncompliance procedures from NYSE due to a stockholders' deficit of $16,167 as of June 30, 2024 [345]. - The company is classified as a smaller reporting company and is not required to disclose certain market risk information [350].

Financial Performance - Total revenues for the three months ended June 30, 2024, were $28,000, compared to $12,000 for the same period in 2023, representing a 133% increase, with the acquisition of Myrtle contributing $20,000 to the increase [165]. - Net loss attributable to FOXO for the three months ended June 30, 2024, was $2,163,000, a reduction of 81% from $11,293,000 in the same period in 2023 [165]. - Net revenues for the six months ended June 30, 2024, were $35, a 40% increase from $25 in the same period of 2023, with the acquisition of Myrtle contributing $20 to the increase [177]. - Net loss attributable to common stockholders was $4,633 for the six months ended June 30, 2024, compared to $21,398 for the same period in 2023, marking a significant improvement of 78% [182]. - Net loss for the six months ended June 30, 2024, was $4,633 thousand, significantly reduced from $21,398 thousand in the same period of 2023 [190]. Expenses - Direct costs of revenues were $31,000 for the three months ended June 30, 2024, compared to no direct costs for the same period in 2023, attributed to the acquisition of Myrtle [166]. - Research and development expenses decreased by 69% to $104,000 for the three months ended June 30, 2024, down from $333,000 in the same period in 2023 [165]. - Total operating expenses decreased by 79% to $1,617,000 for the three months ended June 30, 2024, compared to $7,617,000 in the same period in 2023 [165]. - Selling, general and administrative expenses fell to $1,474 for Q2 2024, down 63% from $4,003 in Q2 2023, primarily due to the completion of a consulting agreement and headcount reductions [170]. - Research and development expenses for the six months ended June 30, 2024, were $269, down 58% from $642 in the same period of 2023, due to lower employee-related expenses [178]. - Selling, general and administrative expenses for the six months ended June 30, 2024, were $2,462, a decrease of 76% from $10,335 in the same period of 2023 [180]. Cash Flow and Financing - Cash and cash equivalents as of June 30, 2024, were $33 thousand, down from $38 thousand as of December 31, 2023 [190]. - Net cash provided by operating activities in the six months ended June 30, 2024, was $551 thousand, compared to cash used of $(5,300) thousand in the same period of 2023, marking an improvement of $5,851 thousand [204]. - Cash used in investing activities for the six months ended June 30, 2024, was $(2,381) thousand, primarily for acquiring an epigenetic software APP and the purchase of Myrtle [206]. - Net cash provided by financing activities in the six months ended June 30, 2024, was $1,825 thousand from the issuance of promissory notes [207]. - The company has a working capital deficit of $20,817 thousand and a total stockholders' deficit of $16,167 thousand as of June 30, 2024 [190]. Operational Strategy - FOXO has paused sales of new life insurance products to conserve cash resources and focus on FOXO Labs [151]. - The company entered into a Letter Agreement with KR8 to develop a Direct-to-Consumer APP utilizing AI technology for epigenetic biomarker applications [153]. - The acquisition of Myrtle on June 14, 2024, marks the company's entry into the healthcare sector, offering behavioral health services including substance abuse treatment [157]. - The company is focusing on commercializing proprietary epigenetic biomarker technology for underwriting risk classification in the life insurance industry [158]. - The company expects to continue incurring operating losses until it achieves adequate scale and secures additional capital [191]. Compliance and Investigations - The company received a notice of noncompliance from NYSE due to a stockholders' deficit of $14.9 million as of March 31, 2024 [220]. - The company has not fully remediated material weaknesses in its internal controls as of the filing date of this report [226]. - The SEC conducted an investigation regarding the termination of Jon Sabes as CEO and Steven Sabes as COO, and the company is voluntarily responding to the SEC's request [230]. - On July 9, 2024, the SEC concluded its investigation and does not intend to recommend enforcement action against the company based on the information available at that time [230].

MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. ("Myrtle"), has been granted two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services, effective August 1, 2024, for 12 months. The first license authorizes the provision of services for alcohol and drug residential detoxification treatment, as well as alcohol and drug residen ...

Core Viewpoint - FOXO Technologies Inc. is currently facing noncompliance issues with the NYSE due to a reported stockholders' deficit of $14.9 million as of March 31, 2024, and losses from continuing operations over the last three fiscal years [6]. Compliance and Regulatory Issues - The company has received an official notice from NYSE Regulation indicating noncompliance with Section 1003(a)(ii) of the Company Guide [6]. - FOXO must adhere to compliance deadlines set by NYSE, including a plan acceptance letter dated August 29, 2023, and must confirm receipt of the NYSE American Notice by July 16, 2024 [1][7]. Management's Response - Mark White, Interim CEO of FOXO, acknowledged the delinquency was due to short-term capital allocation strategies and expressed the company's intention to regain compliance with NYSE standards [3]. - The company is in discussions with NYSE regarding its compliance plan, which includes planned acquisitions expected to generate significant cash flow [3]. Company Overview - FOXO Technologies Inc. is a biotechnology firm focused on enhancing human health and longevity through innovative technology and product solutions, particularly in the life insurance sector [10]. - The company utilizes AI to analyze DNA methylation for identifying molecular biomarkers related to health and aging [10].

Company Overview - FOXO Technologies Inc. is a biotechnology company focused on improving human health and longevity through advanced technology and product solutions, particularly in the life insurance sector [8] - The company utilizes epigenetic technology and AI to analyze DNA methylation for identifying molecular biomarkers related to health and aging [8] Recent Developments - FOXO has filed its Form 10-Q for the quarter ended March 31, 2024, regaining compliance with SEC reporting requirements [1] - The company has successfully closed the Myrtle Recovery Centers transaction on June 14, 2024, and secured a commitment for up to $2.5 million in additional capital [6] - The acquisition of Scott County Community Hospital is pending shareholder approval and is expected to close in the third quarter of 2024 [7] Financial Performance - Myrtle Recovery Centers anticipates generating annual revenues of approximately $3-4 million and aims to replicate its business model in other locations [2] - Scott County Community Hospital and Myrtle Recovery Centers reported unaudited net revenue of approximately $18.7 million and net income of approximately $5.2 million for the twelve months ended December 31, 2023 [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39783 FOXO TECHNOLOGIES INC. 729 N. Washington Ave., Suite 600 Minneapolis, MN 55401 (Address of principa ...

About FOXO Technologies Inc. Mark White, Interim CEO of FOXO, said, "We appreciate the support of this institutional investor, which we believe is further validation of our business model. Specifically, we intend to use the proceeds to complete the acquisition of Myrtle Recovery Centers, Inc., as well as advance our planned acquisition of Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center). As previously noted, we believe these two acquisitions will be transformative for the Company, ...

Additional details on the Senior Notes are available in the Company's Form 8-K, which has been filed with the Securities and Exchange Commission. Forward-Looking Statements This press release contains certain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements about the delisting of the Warrants from NYSE American, tradin ...

MINNEAPOLIS, MN, June 14, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO"), today announced it has entered into two share exchange agreements with Rennova Health, Inc., an OTC listed company ("Rennova") (OTC: RNVA). In the first agreement, equity in Myrtle Recovery Centers, Inc., Rennova's behavioral health services subsidiary, will be exchanged for $500,000 of common stock in FOXO, subject to adjustments. In the second agreement, equity in Rennova Community He ...

Foxo Technologies will acquire the shares of Myrtle Recovery Centers for $500,000. However, it will use shares of FOXO stock to acquire these shares instead of cash. FOXO Stock Movement Today Investors looking for more of the most recent stock market stories will want to stick around! On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That ...